Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY4066434 |
| Synonyms | |
| Therapy Description |
LLY4066434 is a pan-KRAS inhibitor, which potentially decreases growth of tumors harboring KRAS mutations (Cancer Res (2025) 85 (8_Supplement_1): 4375). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY4066434 | LY-4066434|LY 4066434 | KRAS Inhibitor 30 | LLY4066434 is a pan-KRAS inhibitor, which potentially decreases growth of tumors harboring KRAS mutations (Cancer Res (2025) 85 (8_Supplement_1): 4375). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06607185 | Phase I | Leucovorin Cisplatin Nab-paclitaxel LY4066434 Oxaliplatin Irinotecan Carboplatin Gemcitabine Fluorouracil Cetuximab Pemetrexed Disodium Pembrolizumab | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |